Takeda Appoints New President for Millennium: The Takeda Oncology Company

Osaka, Japan, May 9, 2013 --- Takeda Pharmaceutical Company Limited ("Takeda") announced today that effective May 9, 2013, Anna Protopapas, currently Corporate Officer, Executive Vice President and Global Business Development Head, Takeda Pharmaceuticals International, Inc.* located in Deerfield, Illinois, U.S.A., will assume the additional role of President of Millennium: The Takeda Oncology Company* ("Millennium"), based in Cambridge, Mass., U.S.A.

Anna Protopapas, with her extensive strategic leadership experience, has played a pivotal role in a wide range of Takeda global initiatives including leading the acquisition of Nycomed in 2011.

Protopapas will succeed the role of President from Dr. Deborah Dunsire, current President & CEO of Millennium and a member of Takeda's board of directors. Dunsire will retire from Takeda's board after her retirement being resolved at Takeda's Ordinary General Meeting of Shareholders and the Board of Director's Meeting scheduled on June 26, 2013.

* Wholly-owned subsidiaries of Takeda America Holdings, Inc. ("TAH"), located in New York, NY, USA. TAH is a wholly-owned subsidiary of Takeda.

Brief Career History of Anna Protopapas

1990 - 93

Proctor & Gamble International
(International Marketing Manager, International Marketing Development)

1993 - 97

Molten Metal Technology (Director of Business Development)


Millennium Pharmaceuticals Inc. (Director of Business Development)


(Senior Director of Business Development)


(Vice President of Corporate Development)


(Senior Vice President of Corporate Development)

2010 (to present)

Takeda Pharmaceutical International, Inc. 
(Global Business Development Head)

2011 (to present)

(Corporate Officer, Executive Vice President)


Suggested Articles

Novavax delayed the start of a large phase 3 trial for its COVID-19 vaccine in the U.S. and Mexico, thanks to delays in scaling up manufacturing.

The decision to dump IL33r antagonist GSK3772847 follows lackluster clinical data on rival candidates against the same target.  

The deal is worth $50 million upfront but could balloon in value to more than $2 billion if all the milestones are hit.